Literature DB >> 31588101

Statin Intolerance Clinical Guide 2018.

Kouji Kajinami1, Kazuhisa Tsukamoto2, Shinji Koba3, Ikuo Inoue4, Masashi Yamakawa5, Shigeaki Suzuki6, Tadanori Hamano7, Hidetsugu Saito8, Yoshiro Saito9, Satohiro Masuda10, Takeo Nakayama11, Tomonori Okamura12, Shizuya Yamashita13,14, Tatehiro Kagawa15, Junji Kaneyama16, Akira Kuriyama17, Rumi Tanaka10, Aya Hirata12.   

Abstract

Entities:  

Keywords:  Liver injury; Myopathy; Renal dysfunction; Rhabdomyolysis; Statin intolerance

Mesh：

Substances：

Year:  2019        PMID： 31588101      PMCID： PMC7192817          DOI： 10.5551/jat.50948

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.928


× No keyword cloud information.
  82 in total

1.  Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.

Authors:  Connie Newman; John Tsai; Michael Szarek; Don Luo; Eric Gibson
Journal:  Am J Cardiol       Date:  2005-11-15       Impact factor: 2.778

2.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

3.  Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.

Authors:  M Nakata; S Nagasaka; I Kusaka; H Matsuoka; S Ishibashi; T Yada
Journal:  Diabetologia       Date:  2006-05-10       Impact factor: 10.122

4.  The spectrum of hepatotoxicity.

Authors:  H J Zimmerman
Journal:  Perspect Biol Med       Date:  1968       Impact factor: 1.416

5.  Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan.

Authors:  Mayumi Wake; Yoshie Onishi; Florent Guelfucci; Akinori Oh; Shinzo Hiroi; Yukio Shimasaki; Tamio Teramoto
Journal:  Atherosclerosis       Date:  2018-03-16       Impact factor: 5.162

6.  Risk of new-onset diabetes mellitus during treatment with low-dose statins in Japan: A retrospective cohort study.

Authors:  S Kato; M Miura
Journal:  J Clin Pharm Ther       Date:  2018-02-26       Impact factor: 2.512

7.  Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia.

Authors:  Hideki Origasa; Mitsuhiro Yokoyama; Masunori Matsuzaki; Yasushi Saito; Yuji Matsuzawa
Journal:  Circ J       Date:  2010-02-09       Impact factor: 2.993

8.  A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins.

Authors:  Tetsu Watanabe; Kaoru Ando; Hyuma Daidoji; Yoichiro Otaki; Shigeo Sugawara; Motoyuki Matsui; Eiichiro Ikeno; Osamu Hirono; Hiroshi Miyawaki; Yoshinori Yashiro; Satoshi Nishiyama; Takanori Arimoto; Hiroki Takahashi; Tetsuro Shishido; Takehiko Miyashita; Takuya Miyamoto; Isao Kubota
Journal:  J Cardiol       Date:  2017-08-31       Impact factor: 3.159

9.  Cognitive impairment associated with atorvastatin and simvastatin.

Authors:  Deborah S King; Amanda J Wilburn; Marion R Wofford; T Kristopher Harrell; Brent J Lindley; Daniel W Jones
Journal:  Pharmacotherapy       Date:  2003-12       Impact factor: 4.705

10.  Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening.

Authors:  Nobuhiro Ooba; Soko Setoguchi; Tsugumichi Sato; Kiyoshi Kubota
Journal:  BMJ Open       Date:  2017-06-30       Impact factor: 2.692
View more
  3 in total

Review 1.  Rhabdomyolysis-Induced AKI (RIAKI) Including the Role of COVID-19.

Authors:  Ewelina Młynarska; Julia Krzemińska; Magdalena Wronka; Beata Franczyk; Jacek Rysz
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

2.  Development and characterization of a camelid derived antibody targeting a linear epitope in the hinge domain of human PCSK9 protein.

Authors:  Xinyang Li; Jun Hong; Xiaoyan Gao; Meiniang Wang; Naibo Yang
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

3.  Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia.

Authors:  Shizuya Yamashita; Daisaku Masuda; Masahiro Akishita; Hidenori Arai; Yujiro Asada; Kazushige Dobashi; Kensuke Egashira; Mariko Harada-Shiba; Kenichi Hirata; Shun Ishibashi; Kouji Kajinami; Makoto Kinoshita; Koichi Kozaki; Masafumi Kuzuya; Masatsune Ogura; Tomonori Okamura; Kayoko Sato; Hitoshi Shimano; Kazuhisa Tsukamoto; Masayuki Yokode; Koutaro Yokote; Masayuki Yoshida
Journal:  J Atheroscler Thromb       Date:  2020-08-28       Impact factor: 4.928
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.